

Provider Update

August 30, 2022

DOH Deputy Secretary Laura C. Parajón, M.D., M.P.H
Infectious Disease Bureau Chief Dan Burke
IDB Medical Director Miranda Durham, M.D.

NM DOH Mission

To ensure health equity, we work with our partners to promote health and well-being, and improve health outcomes for all people in New Mexico.

Goals



We expand equitable access to services for all New Mexicans



We ensure safety in New Mexico healthcare environments



We improve health status for all New Mexicans




We support each other by promoting an environment of mutual respect, trust, open communication, and needed resources for staff to serve New Mexicans and to grow and reach their professional goals


COVID-19 Overview

COVID-19 Community Levels

A measure of the impact of COVID-19 illness on health and healthcare systems



data through 8/15/22




data through 8/15/22

COVID-19 Community Levels in US by County

	Total	Percent	% Change
High	952	29.55%	- 4.33%
Medium	1383	42.92%	1.78%
Low	887	27.53%	2.55%

[How are COVID-19 Community Levels calculated?](#)

COMMUNITY TRANSMISSION



Community Transmission in US by County


	Total	Percent	% Change
High	2921	90.66%	- 1.21%
Substantial	178	5.52%	1.21%
Moderate	72	2.23%	- 0.09%
Low	51	1.58%	0.09%

How is community transmission calculated?

CDC NowCast

updated 8/27/22

BA.5	VOC	88.7%	87.3-89.8%
BA.4.6	VOC	7.5%	6.4-8.8%
BA.4	VOC	3.6%	3.3-3.8%
BA.2.12.1	VOC	0.2%	0.2-0.3%



COVID in NM - CASES

Community risk level metrics

WEEKLY NEW REPORTED CASES


• **177.1** PER 100K

WEEKLY COVID ADMISSIONS

• **7.1** PER 100K

PATIENTS W/ COVID

• **3.1%** OF ALL BEDS



Over the last week, New Mexico had 3,713 new reported cases (**177.1** for every 100,000 residents). Reported cases do not include all at-home positive tests. Grading is not applied to weekly new reported cases prior to April 18, 2022, indicated by the dotted line. This date marks our change to measure community risk levels, a framework that is only relevant for the current phase of the pandemic. [About this data](#)

Share

<https://www.covidactnow.org/?s=21051026>

COVID in NM - HOSPITAL ADMISSIONS

Community risk level metrics

WEEKLY NEW REPORTED CASES


• **177.1** PER 100K

WEEKLY COVID ADMISSIONS

• **7.1** PER 100K

PATIENTS W/ COVID

• **3.1%** OF ALL BEDS



Over the last week, New Mexico had 149 new COVID hospital admissions (7.1 for every 100,000 residents). Grading is not applied to weekly COVID admissions prior to April 18, 2022, indicated by the dotted line. This date marks our change to measure community risk levels, a framework that is only relevant for the current phase of the pandemic. [About this data](#)

Share

COVID in NM - "R effective"

Transmission metrics

DAILY NEW CASES PER 100K


25.3

INFECTION RATE

0.93

POSITIVE TEST RATE

15.8%



On average, each person in New Mexico with COVID is infecting 0.93 other people. If this number is over 1.0, it means that the total number of COVID cases is growing. About this data

Share

All metrics

METRIC


Hospitalizations (w/ COVID per 100k) ▼

PAST # OF DAYS


60 ▼

LOCATIONS

New Mexico; New York; California; ... ▼




New Mexico COVID-19 Vaccine Administration



NMSIIS and Tiberius data


Daily Doses Administered (All Doses): 6 months to 4 year olds

Updated: 2022-08-23




Vaccines Administered Within the Last Two Weeks (All Ages)

Period: 07-Aug-22 to 23-Aug-22



First Boosters by Provider Type



- OTHER
- PRIVATE PRACTICE
- INDIAN HEALTH
- HOSPITAL
- PHARMACY
- PUBLIC HEALTH DEPT
- FQHC
- PUBLIC CLINIC/NON HEALTH DEPT

Vaccine Updates



Timeline (cont.)

- 12.8.21 FDA authorizes AstraZeneca's Evusheld for emergency use
- 12.9.21 Pfizer boosters approved for 16 - 17-year-olds
- 12.22.21 FDA authorizes Pfizer's Paxlovid for emergency use
- 12.23.21 FDA authorizes Merck's Molnupiravir for emergency use
- 1.3.22 FDA authorizes Pfizer vaccine boosters for everyone 12+ and expanded 3rd dose for immune compromised individuals to include 5 - 11
- 1.3.22 FDA changes booster dose time frame for Pfizer to "at least 5 months from primary series completion "
- 1.7.22 NM DOH recommends halting BAM/ETE and REGEN-COV due to high proportion of Omicron
- 1.7.22 FDA changes booster dose time frame for Moderna to "at least 5 months from primary series completion"
- 1.31.22 Moderna's SpikeVax FDA approved
- 2.4.22 Moderna's SpikeVax endorsed by ACIP and CDC
- 2.11.22 booster interval for immune compromised people changed to 3 months (and other changes)
- 2.11.22 Bebtelovimab approved (Eli Lilly) for 12+
- 2.17.22 NM mask mandate lifted - except in healthcare, LTCF's, residential treatment centers, State prisons, juvenile justice
- 2.21.22 change to weekly vaccine reporting (on Tuesdays)
- 2.22.22 vax interval changed to allow up to 8 weeks between first and second doses
- 2.23.22 texts sent to immune compromised individuals (40K texts)
- 2.24.22 FDA amends Evusheld EUA - recommending dose increase
- 3.29.22 FDA/CDC approve a 2nd mRNA booster for 50+ and for people 12+ with immune compromise
- 4.5.22 Sotrovimab EUA revoked by FDA
- 4.13.22 FDA extends mask mandate on public transport thru 5/3; federal judge strikes it down on 4.18.22
- 4.14.22 FDA grants EUA for first COVID19 "breath test" (InspectIR COVID-19 Breathalyzer test detects 5 VOCs in exhaled breath)
- 4.15.22 NM Public Health order renewed through 5/16
- 5.19.22 CDC recommends single booster for kids 5 - 11
- 6.7.22 VRBPAC recommends Novavax
- 6.18.22 CDC recommends Moderna for kids 6mo - 5yo and Pfizer for kids 6mo - 4yo
- 6.24.22 CDC recommends Moderna for kids 6 - 17 years
- 7.8.22 FDA *approves* COMIRNATY for 12+
- 7.19.22 CDC recommends Novavax for people 18+
- 8.20.22 FDA extends Novavax EUA to cover people 12 - 17 yo
- 8.22.22 CDC approves Novavax for 12 - 17 year olds (by decision memo)

CDC Recommends Novavax COVID-19 Vaccine for Adolescents

Media Statement

For Immediate Release: Monday, August 22, 2022

Contact: [Media Relations](#)

(404) 639-3286

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., signed a decision memo that Novavax's COVID-19 vaccine be used as another primary series option for adolescents ages 12 through 17. This recommendation follows FDA's authorization to authorize the vaccine for this age group under emergency use. Novavax's COVID-19 vaccine, which is available now, is an important tool in the pandemic and provides a more familiar type of COVID-19 vaccine technology for adolescents. Having multiple types of vaccines offers more options and flexibility for the public, jurisdictions, and vaccine providers.

Novavax's COVID-19 vaccine packages harmless proteins of the COVID-19 virus alongside another ingredient called an adjuvant that helps the immune system respond to the virus in the future. Vaccines—like the Novavax COVID-19 vaccine—that use protein subunit technology have been used for more than 30 years in the United States, beginning with the first licensed hepatitis B vaccine. Other protein subunit vaccines used in the United States today include those to protect against influenza and whooping cough (acellular pertussis).

COVID-19 vaccine products currently approved or authorized in the United States

Pfizer-BioNTech							
Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses	
				Dose	Injection volume	Dose	Injection volume
6 months–4 years	Maroon	Maroon	Yes	3 µg	0.2 mL	NA	NA
5–11 years	Orange	Orange	Yes	10 µg	0.2 mL	10 µg	0.2 mL
12 years and older	Purple	Purple	Yes	30 µg	0.3 mL	30 µg	0.3 mL
12 years and older	Gray	Gray	No	30 µg	0.3 mL	30 µg	0.3 mL
Moderna							
Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses	
				Dose	Injection volume	Dose	Injection volume
6 months–5 years	Dark blue	Magenta	No	25 µg	0.25 mL	NA	NA
6–11 years	Dark blue	Purple	No	50 µg	0.5 mL	NA	NA
12–17 years	Red	Light blue	No	100 µg	0.5 mL	NA	NA
18 years and older	Red	Light blue	No	100 µg	0.5 mL	50 µg	0.25 mL
18 years and older	Dark blue	Purple	No	NA	NA	50 µg	0.5 mL
Janssen Janssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety considerations. For guidance on respective record review, scheduling and administration of Janssen vaccine see Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendix A (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)							
Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses	
				Dose	Injection volume	Dose	Injection volume
18 years and older	Blue	No Color	No	5×10 ¹⁰ viral particles	0.5 mL	5×10 ¹⁰ viral particles	0.5 mL
Novavax							
Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses	
				Dose	Injection volume	Dose	Injection volume
12 years and older	Royal blue	No Color	No	5 µg rS and 50 µg of Matrix-M™ adjuvant	0.5 mL	N/A	N/A

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

NOVAVAX Updated EUAs

Fact Sheets (English)

Information	Last Updated
Fact Sheet for Healthcare Providers Administering Vaccine	August 19, 2022
Fact Sheet for Recipients and Caregivers	August 19, 2022

Translations of the Fact Sheet for Recipients and Caregivers

接受者和护理者须知 (August 19, 2022)	中文 (Chinese, Simplified)
환자와 의료진을 위한 정보지 (August 19, 2022)	한국어 (Korean)
HOJA INFORMATIVA PARA RECEPTORES Y PROVEEDORES DE CUIDADO (August 19, 2022)	Español (Spanish)
FACT SHEET PARA SA MGA TATANGGAP AT MGA TAGAPAG-ALAGA (August 19, 2022)	Tagalog (Tagalog)
TỜ THÔNG TIN CHO NGƯỜI NHẬN VÀ NHỮNG NGƯỜI CHĂM SÓC (August 19, 2022)	Tiếng Việt (Vietnamese)

[Novavax COVID-19 Vaccine, Adjuvanted | FDA](#)


BIVALENT COVID-19 BOOSTERS

- FDA meeting 8/31 (no VRBPAC meeting).
- ACIP meeting 9/1 - 9/2 pending FDA EUA.
- The Bivalent Boosters are only for booster doses for those who have completed the 2-dose primary series (or 3 doses for people with immune compromise).
- The current adult vaccines (Pfizer ADU EUA, Comirnaty, Spikevax, Moderna ADU EUA) will be for primary series.
- At least one pediatric bivalent booster is likely to follow
- Expect co-administration with other vaccines to be OK

Pfizer BIVALENT 12+

- Both the Pfizer adult EUA/Comirnaty and the Pfizer bivalent booster will look the same with a **Grey Cap/Grey** vial label.
- Look closely for **"BIVALENT"** on the label
- Same dose: 30 mcg/0.3mL dose
- No dilution required
- Storage: ULT 12 months or refrigerator 10 weeks
- Discard 12 hours after 1st puncture
- A new fact sheet will be created for providers; caregiver one will be updated
- Pfizer NDC: 59267-0304-02
- Single dose vials - coming soon?

Pfizer



weekly → daily Pfizer webinars:


<https://www.pfizermedicalinformation.com/en-us/medical-updates>

Gray Cap Multidose Vial Labels - 12 Years and Older (DO NOT DILUTE)

Pfizer-BioNTech COVID-19 Vaccine or Comirnaty® (COVID-19 Vaccine, mRNA) Primary Series Only



Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) Booster Dose Only



FOR TRAINING PURPOSES ONLY

THE PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5) HAS NOT BEEN AUTHORIZED FOR USE

Moderna BIVALENT 18+

- Dark Blue Cap/Grey Border
- 0.5mL/50mcg (5 dose vials)
- Storage: Freezer (expiration date), refrigerator-30 days, room temp-24hrs.
- DO NOT REFREEZE
- Discard 12 hours after 1st puncture
- Will have educational sessions
- QR Code for expiration look-up
- Moderna NDC:80777-0282-99

Moderna COVID-19 Bivalent Vaccine Presentation

Bivalent Booster Dose Presentation

**DRAFT – SUBJECT TO
CHANGE PENDING
REGULATORY
GUIDANCE AND
AUTHORIZATION/
APPROVAL – SHARED
FOR PLANNING
PURPOSES ONLY**

Age Group	18+ years of age	
Dose Volume	Bivalent Booster Dose: Each 0.5 mL (50 mcg)	
Dose Per Vial	5 doses	
Vial Cap Color	Dark Blue	
Vial Label	Gray Border NDC 80777-285-05	
Carton	Gray Border NDC 80777-285-99	

Slide 2

Confidential & Proprietary. Do not distribute. © 2021 Moderna Therapeutics

moderna

What we don't know at this time?

- CPT codes
- Interval spacing for last dose - probably 2 months
- Clinical considerations
- Demand

New Mexicans 18+ With Primary Series Complete

1,308,332

BIVALENT BOOSTER LOGISTICS

- Waves 1 and 2 have been ordered and will be sent out once the EUA is approved.
- Regular ordering will begin in NMSIIS Tuesday September 6th

The table below summarizes when vaccine will or will not be delivered over the holiday.

2022	Sat, Sept. 3	Sun, Sept. 5	Mon, Sept. 6	Tues, Sept. 6	Wed, Sept. 7
Pfizer	No Deliveries	No Deliveries	No Deliveries	Thur Orders Delivered *	Deliveries
McKesson Specialty	No Deliveries	No Deliveries	No Deliveries	No Deliveries	Deliveries

Vaccine Effectiveness (VE) Estimates, March–July 2022

The publications in the table are organized by date of publication, with the most recent first. Studies that included more than one outcome or multiple age groups are listed more than once and the table can be sorted by these variables.

<div> <div> Outcome <ul style="list-style-type: none"> <input type="radio"/> All outcomes <input type="radio"/> SARS-CoV-2 infection <input type="radio"/> Critical illness <input type="radio"/> Emergency department/urgent care visits <input checked="" type="radio"/> Hospitalization <input type="radio"/> Invasive mechanical ventilation (IMV) or death </div> <div> Age Group <ul style="list-style-type: none"> <input checked="" type="radio"/> All age groups <input type="radio"/> Adults <input type="radio"/> Adolescents <input type="radio"/> Children <input type="radio"/> Infants </div> </div>							
Outcome	Vaccine effectiveness*	Age Group	Vaccine(s) [#]	Population	Study period	Monitoring System	Publication Date/Journal/First author
Hospitalization	61% for 2 doses during BA.1 92% for 3 doses 7–119 days after 3 rd dose during BA.1 85% for 3 doses ≥120 days after 3 rd dose during BA.1 24% for 2 doses during BA.2/BA.2.12.1 69% for 3 doses 7–119 days after 3 rd dose during BA.2/BA.2.12.1 52% for 3 doses ≥120 days after 3 rd dose during BA.2/BA.2.12.1 55% for 3 doses among ≥50yo ≥120 days after 3 rd dose during BA.2/BA.2.12.1 80% for 4 doses among ≥50yo >1 week after 4 th dose during BA.2/BA.2.12.1	Adults	mRNA	10 states	Dec 18, 2021–Jun 10, 2022	VISION	7/22/2022 MMWR, Link-Gelles R
Hospitalization	52% overall 70% against ICU admission 47% against non-ICU hospitalization 80% during Delta 38% during Omicron 69% for either variant when maternal vaccination occurred after 20 weeks of pregnancy 38% when maternal vaccination occurred during the first 20 weeks of pregnancy	Infants (<6 months)	mRNA (maternal vaccination)	30 pediatric hospitals across 22 states	Jul 1, 2021–Mar 8, 2022	Overcoming Covid-19	6/22/2022 NEJM, Halasa NB

COVID Vaccine Expiry Lookup Tools

- Moderna
 - <https://eua.modernatx.com/covid19vaccine-eua/providers/vial-lookup>
- Janssen
 - <https://vaxcheck.jnj/>
- Novavax
 - <https://us.novavaxcovidvaccine.com/hcp>
- Pfizer
 - <https://lotexpiry.cvdvaccine.com/>

Other COVID Updates



FEDERAL AT-HOME TEST PROGRAM ENDING

COVID.gov

English Español 简体中文


Ordering through this program will be suspended on Friday, September 2 because Congress hasn't provided additional funding to replenish the nation's stockpile of tests.

Get free at-home COVID-19 tests

Every home in the U.S. is eligible to order a 3rd round of free at-home tests. Order yours today.

[Order Free At-Home Tests](#)

Need help placing an order for your at-home tests?
Call [1-800-232-0233](tel:1-800-232-0233) (TTY [1-888-720-7489](tel:1-888-720-7489)).



Project ACT - available through Feb 2023

Mail Order a Free At-Home COVID-19 Test

Rapid Antigen Test - Results in 15 Minutes – Order for when you need them!



Free at-home COVID-19 Tests through Project ACT


5 tests per household while supplies last. Orders usually ship in 2-5 days.

Your zip code is eligible to order free at-home COVID-19 tests through Project Act, a partnership between the state of NM and the Rockefeller Foundation to support communities in zip codes that have been disproportionately affected by COVID. Learn more: Project ACT | Home (accesscovidtests.org)

[Click Here to Order Your Tests Now](#)


[COVID-19 Screening & Testing Sites - New Mexico Department of Health \(findatestnm.org\)](https://findatestnm.org)

Monkeypox Updates




MONKEYPOX

18,101 US cases



<https://www.cdc.gov/poxvirus/monkeypox/response/2022/us-map.html>


U.S. Monkeypox Case Trends Reported to CDC



Cases Reported in 2022


<https://www.cdc.gov/poxvirus/monkeypox/response/2022/mpx-trends.html>

Monkeypox cases reported to CDC: Age and Gender



<https://www.cdc.gov/poxvirus/monkeypox/response/2022/demographics.html>


Monkeypox cases reported to CDC: Symptoms



<https://www.cdc.gov/poxvirus/monkeypox/response/2022/demographics.html>

FDA NEWS RELEASE


Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply



JYNNEOS VACCINE - Alternate Dosing

MONKEYPOX

How to administer a JYNNEOS vaccine intradermally



STEP 3

Slowly inject 0.1 mL intradermally. This should produce a noticeable pale elevation of the skin (wheal).

www.cdc.gov/monkeypox

Step 3: Slowly inject 0.1 mL intradermally. This should produce a noticeable pale elevation of the skin (wheal).

Table 2. Vaccination Schedule and Dosing Regimens for JYNNEOS Vaccine

JYNNEOS vaccine regimen	Route of administration	Injection volume	Recommended number of doses	Recommended interval between 1st and 2nd dose
Alternative regimen				
People age ≥ 18 years	ID	0.1 mL	2	28 days
Standard regimen				
<u>People age <18 years</u>	Subcut	0.5 mL	2	28 days
People of any age who have a history of developing keloid scars	Subcut	0.5 mL	2	28 days

Vaccine Registration

- Source: RTS Extraction Date: 08/24/2022



NMDOH Monkeypox site:
<https://www.nmhealth.org/about/phd/idb/mpv/>



MONKEYPOX

How do I get vaccinated?

If you think you are at risk for Monkeypox and are interested in a vaccine

REGISTER BY PHONE:

Call the **NM Department of Health (NMDOH) Call Center at 1-855-600-3453, Option 4** for a confidential consultation.

REGISTER ONLINE:

Visit: **monkeypoxnm.org**
You will be invited to schedule a vaccine appointment based on your risk.




NMDOH

For more information about monkeypox, visit:
[nmhealth.org/about/phd/idb/mpv](https://www.nmhealth.org/about/phd/idb/mpv/)

Guidance

Situation*	Lowest Risk	Intermediate Risk	Higher Risk
Living Space	<p>Remain alone in a home or where only others with monkeypox are located.</p> <p>Cover upholstered furniture and porous materials that cannot be washed with sheets, blankets, tarps, and other covers.</p>	<p>Remain in a separate room in a home or facility away from others who do not have monkeypox.</p> <p>Cover all upholstered furniture and porous surfaces with sheets, blankets, tarps, or other covers.</p> <p>Wear a well-fitting mask and cover lesions while around others.</p> <p>Disinfect surfaces (doorknobs, countertops) between each use.</p>	<p>Share space with others but avoid close contact. Do not share a bed with another person.</p> <p>Wear a well-fitting mask and cover lesions while around others.</p> <p>Disinfect surfaces (doorknobs, countertops) between each use.</p>



<https://www.cdc.gov/poxvirus/monkeypox/if-sick/preventing-spread.html>

<https://www.cdc.gov/poxvirus/monkeypox/specific-settings/home-disinfection.html>

Instructions for monkeypox specimen collection for SLD:

1. Call NM DOH ERD call line 505-827-0006. Patients can be directed to 1-855-600-3453 (COVID call line).
2. Use personal protective equipment (PPE) for standard, contact, and droplet precautions. (mask, eye protection, gown, gloves)
3. If the patient has multiple lesions, swab up to 4 lesions, preferably from different locations on the body and/or from lesions with differing appearances.
4. Vigorously swab each lesion **with two** separate sterile dry polyester or Dacron swabs (one sample for preliminary and one for confirmatory testing at CDC). Do not use cotton swabs.
5. Place each swab in a separate “sterile” container such as a urine cup or pour-off tube (plastic preferred).
6. **Do not add or store in viral or universal transport media.**
7. Each lesion site that is sampled requires a separate test requisition form. Put both samples from one site in the biohazard bag with one requisition. <https://www.nmhealth.org/publication/view/form/6380/>
8. Immediately refrigerate samples (2-8°C), and contact NMDOH Epidemiology Division 24/7 at (505)-827-0006.
9. NMDOH will provide shipping instructions.
10. TRICORE is now sending MPX specimens to Mayo Clinic Lab. Results will come back via normal channels (by fax or to EHR's).

DOH Contact Information for Providers

CONTACT INFO	DESCRIPTION
Epidemiology and Response Division 505-827- 0006	Epidemiologist on call for guidance on any reportable diseases (monkeypox, measles, rabies, etc)
COVID.Vaccines@state.nm.us	COVID-19 Vaccine Record requests; Provider COVID-19 Vaccine Order status; NMSIIS assistance.
COVID.Therapeutics@state.nm.us	Provider questions regarding COVID therapeutics
COVIDData.compliant@state.nm.us	COVID-19 vaccine storage and handling questions, temperature log and onboarding Vaccine Plan submissions.
COVID.testing-doh@state.nm.us	For Provider questions on testing and test supplies

DOH Contact Information for Patients

CONTACT INFO	DESCRIPTION
COVID-19 Call Center: 1-855-600-3453	Users who have questions or would like support with COVID vaccine registration and testing Taking Monkeypox questions and registering people for MPX Vaccine (Jynneos)
ALTSD assistance: 1-800-432-2080	For seniors and those with disabilities who need support with vaccine registration and scheduling.
1-833-551-0518	For non-health related COVID-19 questions



THANK YOU
for all that
you do!